Bayer's MRI Contrast Agent Gets Panel Endorsement, But Without Comparative Safety Claims
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Peripheral and Central Nervous System Drugs Advisory Committee declines to deem gadobutrol "lower risk" for causing nephrogenic systemic fibrosis.